| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Measuring Creativity, DIY style |
|
Advice You - Measuring Creativity, DIY style
Creativity measurement is often required in order to benchmark existing competencies, monitor improvement, increase output and generally provide tangible and useable p According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product rocesses and structures for clients. Individuals can measure their own creativity, the creativity levels of their group, department or organisation. However, a funda ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ental lack of understanding of creativity and innovation seems to make this a difficult task for many. First, we need to define the difference between creativity and lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. nnovation. Creativity can be defined as problem identification and idea generation whilst innovation can be defined as idea selection, development and commercialisatio here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe n. This reveals at least two issues: a) Creative measurement requires isolation of problems and ideas. b) Innovation measurement requires isolation of idea selection d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro development and commercialisation processes. The above means that creativity can be measured without the production of a final, commercially successful product or se ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc vice. We can simply measure how good an organization is at identifying problems and generating ideas. If an organization scores relatively high at this stage (and is n easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ot producing adequate commercial output), we can then look deeply at their innovation processes. Second, we need a measurement system. A very simple and often used qu nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ntitative system is to list criteria and rate them on a scale. A rating before and after, say, a training session or activity, will indicate tangible levels of change. and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ Third, we need to discern the criteria we will measure. There are in fact a number of definitions of creativity. One of the most useful is that it is: a) The produc ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ion of a quantity of ideas. b) The production of a number of diverse ideas. c) The production of a number of novel ideas. Using all of the above, we can begin const ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ructing a quantitative sheet that lists: a) Problem identification b) Generation of a number of ideas c) Generation of a number of diverse ideas d) Generation of a dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod number of novel ideas. For each criterion above, we can grade, for example, from 1 to 10, before and after a training session. We can also grade before and after an a cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin tivity or an idea generating technique (lateral thinking, association, linking etc), in order to gauge the exact value of each tool. All of the above is, in fact, not tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen rocket science. Going a bit deeper. Each of the above criteria can be extrapolated to draw out the analysis (number of different perspectives used to analyse proble t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel , number of dominant ideas basing the problem etc). To construct a much more meaningful analysis, travel down the following path: Each environment consists of a rang ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust of dimensions that affect creativity. On an organizational level, for example, we can measure attitudes, competency make-up, organizational structure, organizational y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products culture, team structure, knowledge mix and so forth. These and other topics are covered in depth in the MBA dissertation on Managing Creativity & Innovation, which ca . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de be purchased (along with a Creativity and Innovation DIY Audit, Good Idea Generator Software and Power Point Presentation) from http://www.managing-creativity.com Ka elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip Bishop, MBA ********************************** You are free to reproduce this article as long as no changes are made and the author's name and site URL are retained tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Accounts Receivable Conversion! A Major Money & Time Saver For Companies Do You Go Home From Work Tired Downsizing in Organisations - The Real Truth
|